Effects of sotatercept on lung diffusion capacity and blood gases in patients with pulmonary arterial hypertension

被引：1
|
作者：
Olsson, Karen M. [1 ,2 ]
Fuge, Jan [1 ,2 ]
Park, Da-Hee [1 ,2 ]
Kamp, Jan C. [1 ,2 ]
Brod, Torben [1 ,2 ]
Harrigfeld, Britta [1 ,2 ]
Schupp, Jonas C. [1 ,2 ]
Hoeper, Marius M. [1 ,2 ]
机构：
[1] Hannover Med Sch, Dept Resp Med & Infect Dis, Hannover, Germany
[2] German Ctr Lung Res DZL, Biomed Res Endstage & Obstructive Lung Dis Hanover, Hannover, Germany
来源：
EUROPEAN RESPIRATORY JOURNAL | 2023年 / 62卷 / 02期
关键词：
THERAPY;
D O I：
10.1183/13993003.01070-2023
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Arterial And Transcutaneous Gases In Pulmonary Hypertension
    Cikach, F.
    Dweik, R. A.
    Tonelli, A. R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [42] Effects of accupro on the pulmonary function test and blood gases in patients with hypertension and obstructive pulmonary diseases
    Shilova, H
    Adasheva, T
    Zadiontchenko, V
    JOURNAL OF HYPERTENSION, 2002, 20 : S395 - S395
  • [43] COMPARISON OF EFFECTS OF INHALED TREPROSTINIL ON LUNG FUNCTION IN PATIENTS WITH PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE AND PULMONARY ARTERIAL HYPERTENSION
    Nathan, Steven
    Tapson, Victor
    Ramani, Gautam
    Medarov, Boris
    Levine, Deborah
    Burger, Charles
    El-Kersh, Karim
    Shen, Eric
    Rao, Youlan
    Smith, Peter
    Waxman, Aaron
    CHEST, 2021, 160 (04) : 2244A - 2246A
  • [44] Diffusion capacity and BMPR2 mutations in pulmonary arterial hypertension
    Trip, Pia
    Girerd, Barbara
    Bogaard, Harm-Jan
    de Man, Frances S.
    Boonstra, Anco
    Garcia, Gilles
    Humbert, Marc
    Montani, David
    Vonk-Noordegraaf, Anton
    EUROPEAN RESPIRATORY JOURNAL, 2014, 43 (04) : 1195 - 1198
  • [45] Redefining Pulmonary Arterial Hypertension Treatment: Sotatercept's FDA Priority Review
    Kumar, Harendra
    Dhali, Arkadeep
    Biswas, Jyotirmoy
    Dhali, Gopal Krishna
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (08)
  • [46] FDA approves Merck & Co's pulmonary arterial hypertension drug sotatercept
    Kingwell, Katie
    NATURE REVIEWS DRUG DISCOVERY, 2024, 23 (05) : 327 - 327
  • [47] Prognostic Value of the Multicomponent Improvement (MCI) Endpoint in Patients With Pulmonary Arterial Hypertension (PAH) Treated With Sotatercept
    Waxman, A. B.
    Badesch, D. B.
    Gibbs, J. S. R.
    Ghofrani, H. A.
    Gomberg-Maitland, M.
    Humbert, M. J.
    Mclaughlin, V. V.
    Preston, I. R.
    Souza, R.
    Grunig, E.
    Kope, G.
    Meyer, G. Bohns
    Olsson, K. M.
    Rosenkranz, S.
    Zhao, Y.
    Lau, A.
    Cornell, A. G.
    Pena, J.
    Hoeper, M. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [48] EFFECTS OF AN ULTRASONIC AEROSOL ON PULMONARY MECHANICS AND ARTERIAL BLOOD GASES IN PATIENTS WITH CHRONIC BRONCHITIS
    PFLUG, AE
    CHENEY, FW
    BUTLER, J
    AMERICAN REVIEW OF RESPIRATORY DISEASE, 1970, 101 (05): : 710 - &
  • [49] Sotatercept: A First-In-Class Activin Signaling Inhibitor for Pulmonary Arterial Hypertension
    Miranda, Aimon C.
    Cornelio, Cyrille K.
    Tran, Bao Anh C.
    Fernandez, Joel
    JOURNAL OF PHARMACY TECHNOLOGY, 2025,
  • [50] Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension
    Lewis, Robert A.
    Thompson, A. A. Roger
    Billings, Catherine G.
    Charalampopoulos, Athanasios
    Elliot, Charlie A.
    Hamilton, Neil
    Hill, Catherine
    Hurdman, Judith
    Rajaram, Smitha
    Sabroe, Ian
    Swift, Andy J.
    Kiely, David G.
    Condliffe, Robin
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
12345